Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : MAP 315
Therapeutic Area : Immunology
Study Phase : Phase I
Recipient : Microba Life Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Microba Commences Phase I Clinical Trial for IBD Therapeutic
Details : MAP 315 is a live biotherapeutic product (LBP) consisting of lyophilised bacteria in an enteric coated capsule which is orally administered and being developed as an investigational product for the treatment of IBD and ulcerative colitis (UC).
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
June 27, 2023
Lead Product(s) : MAP 315
Therapeutic Area : Immunology
Highest Development Status : Phase I
Recipient : Microba Life Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Firmicute Species Bacterial Spore
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Seres Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration with Bacthera will expand the commercial production capacities of SER-109 and provide supply support. SER-109, Seres’ lead product candidate for recurrent Clostridioides difficile infection (rCDI).
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Undisclosed
October 11, 2021
Lead Product(s) : Firmicute Species Bacterial Spore
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Seres Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Reset All
